By R. Anktos. University of Charleston.
End-of-treatment but not Eastern Cooperative Oncology Group cheap clomiphene 100mg with mastercard. Randomized comparison of 142 American Society of Hematology low-dose involved-ﬁeld radiotherapy and no radiotherapy for children 43 order clomiphene 50 mg online. Good enough: a primer on the analysis and with Hodgkin’s disease who achieve a complete response to chemo- interpretation of noninferiority trials. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, Group C. ABVD alone reduction improves outcome prediction of positron emission tomography/ versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. Interim-treatment quantitative comparison of combined modality therapy and ABVD alone for patients PET parameters predict progression and death among patients with with limited-stage Hodgkin lymphoma. Long-term results of CCG 5942: a tumour volume is an independent prognostic factor in Hodgkin lym- randomized comparison of chemotherapy with and without radiotherapy phoma. Point/counterpoint: early-stage Hodgkin lym- tomography for oncology applications. Quantitative diffusion phoma: pretreatment prognostic factors and interim PET. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Vermoolen MA, Kersten MJ, Fijnheer R, van Leeuwen MS, Kwee TC, Prognostic value of interim FDG-PET after two or three cycles of Nievelstein RA. Tailored therapy in Hodgkin positron emission tomography/computed tomography for assessment of lymphoma, based on predeﬁned risk factors and early interim PET/CT, response to brentuximab vedotin treatment in relapsed and refractory Israeli H2 protocol: preliminary report on 317 patients [abstract]. Omitting radiotherapy in sequential therapy with brentuximab vedotin and augmented ICE early positron emission tomography-negative stage I/II Hodgkin lym- followed by autologous stem cell transplant for relapsed and refractory phoma is associated with an increased risk of early relapse: clinical Hodgkin lymphoma [abstract]. Involved ﬁeld radiotherapy with ABVD or AVD for patients with newly diagnosed Hodgkin’s versus no further treatment in patients with clinical stages IA and IIA lymphoma: a phase 1, open-label, dose-escalation study. Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD: 2013;14(13):1348-1356. Gopal1,2 1Department of Medicine and 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA Classical Hodgkin lymphoma (HL) relapses after or is refractory to upfront multiagent chemotherapy in 20%–30% of patients. Effective salvage therapy for relapsed or refractory HL is limited, and advancements are needed. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated signiﬁcant activity and manageable toxicities in advanced HL. Currently approved as a monotherapy for patients with HL that is relapsed or refractory to multiple lines of chemotherapy or autologous stem cell transplantation, BV is now being evaluated earlier in the course of disease and in combination with other therapies. This review discusses the successful translation of BV from its conception to the clinical setting and highlights ongoing trials that may ultimately expand its role in relapsed or refractory HL and improve outcomes for patients. After BV’s target-cell binding and internaliza- Learning Objectives tion, the dipeptide linker is cleaved through lysosome-mediated ● BV has expanded the therapeutic options for relapsed or proteolysis and MMAE is released into the cytoplasm, where it is refractory Hodgkin lymphoma active in its naked form and rapidly induces apoptosis. Nathwani et al examined tumor expression of CD30 in 2 relapsed or refractory (RR) disease remains a signiﬁcant challenge. Brentuximab vedotin (BV) has recently been proven The ﬁrst human trial of BV was a landmark phase 1 study in 45 beneﬁcial in this setting and thus has been added to available patients (42 of whom had RR HL) with CD30-positive malignan- cies. Doses were This review covers the initial data supporting the approval of BV increased stepwise from 1. Steady-state pharmacokinetics for both components was Background observed by 21 days, supporting the 21-day dosing schedule. Mechanism of action of BV Predominant observed toxicities were grade 1-2 in severity and BV’s origin lies with the identiﬁcation of CD30, a cell membrane included fatigue, pyrexia, diarrhea, nausea, neutropenia, and neurop- protein that in healthy individuals has limited expression outside of athy, resulting in dose delays in 36% of subjects; the MTD was activated T and B lymphocytes. Tumor regression was certain virally infected cells and several types of malignancies, observed in 39 of 45 treated patients, with 17 classiﬁed as having an including HL Reed-Sternberg cells. It has long been recognized as objective response (OR) including 11 complete responses (CRs). Pharmaceutical targeting of CD30 dates back ranted further testing of BV in HL. Of the more highly toxic payload, the antimitotic tubulin-inhibitor monomethyl common and mild toxicities mentioned in the previous paragraph, Hematology 2014 151 Table 1. Selected studies of BV for HL after auto-SCT Year Study reported Disease state Treatment Study type Patients, n Key results Younes et al7 2010 Relapse (after BV for 3 weeks (dose Phase 1 42* 86% tumor regression auto-SCT)* escalation) Younes et al12 2012 Relapse after auto- BV 1. It is thought to be (PR), indicating the potential impact of remission quality on due to MMAE’s potent antitubulin properties on distal neurons.
For detailed information see page: 74 Emtriva cheap clomiphene 100 mg without prescription, see Emtricitabine cheap clomiphene 25 mg on line. Ethambutol Manufacturer: among others Riemser Several generics. Indications and trade names: tuberculosis, MAC infection. It is usually reversible if ethambutol is discontinued immediately. Other side effects: nausea, vomiting, abdominal pain, headache, dizziness, pruritus, arthralgia, elevated serum uric acid (possible acute gout attacks), abnormal liver function tests. Interactions, warnings: ethambutol is contraindicated with pre-existing optical nerve damage. Ophthalmologic examination before initiation of treatment and subsequently at 4-week intervals (color discrimination, field of vision, acuity). Immediate discontinuation to prevent optical atrophy if vision impairment occurs. Patients should be informed that impairment of vision may occur and to immedi- ately report this to the treating physician. Aluminum hydroxide reduces absorption of ethambutol; ethambutol should therefore be taken at least one hour before antacids. Monitor liver values and uric acid levels at monthly intervals. Indications and trade name: in combination with a boosted PI and other anti- retroviral agents for the treatment of HIV-1 infection in antiretroviral treatment- experienced adult patients and in children aged 6 years or older. With mild exanthema, which usually appears in the second week, treatment can usually be continued, immediately stop- ping at a serious exanthema. In October 2009, the company published a Dear Doctor letter, reporting on three cases of TEN. Interactions, warnings: etravirine is a substrate of the CYP450 enzyme system as well as an inducer of CYP3A4 and an inhibitor of CYP2C9, therefore, some interac- tions are to be anticipated. Etravirine reduces the serum concentrations of atazanavir, maraviroc and raltegravir and increases fosamprenavir levels. On the other hand, etravirine levels are considerably reduced by tipranavir, efavirenz and nevirapine (moderately by darunavir, saquinavir and tenofovir). Lopinavir and delavirdine increase the levels of etravirine. Etravirine should not be combined with the following: atazanavir, fosamprenavir, tipranavir, unboosted PIs or other NNRTIs. Avoid rifampicin, carbamazepine, phe- nobarbital, phenytoin and St. Drug Profiles 695 Comments: etravirine is the first second-generation NNRTI that was licensed in 2008 for pre-treated patients. It is well-tolerated and effective against some (but not all) NNRTI-resistant HIV strains. Should be combined with a boosted PI (preferably darunavir, due to the lack of data with other PIs). For detailed information see page: 84 Eviplera, see Complera. Evotaz, see Atazanavir and Cobicistat Exviera, see Dasabuvir. Fluconazole Manufacturers and trade names: Pfizer and many other companies, therefore several trade names, such as Diflucan, Fluconazole CT/Stada, or Flucobeta. Indications: Candida infection, cryptococcal meningitis and some rare mycoses. Suspension, 50 mg per 10 ml • Fluconazole IV for injections, 100, 200 and 400 mg Dosage: for oral candidiasis, 100 mg QD orally; for candida esophagitis 200 mg QD for 7–10 days. An attempt with a higher dose (up to 800 mg daily) may be made if there is persistent candidiasis after 10 days.
9 of 10 - Review by R. Anktos
Votes: 108 votes
Total customer reviews: 108